Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Whitney B Pope

Showing results (111-120 of 128) with videos related to

Pageof 13
Sort By:
Neuro-Oncology|October 15, 2014
Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD)Patrick Y Wen, Timothy F Cloughesy, Benjamin M Ellingson, et al.
Neuro-Oncology|December 5, 2021
Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitorsAkifumi Hagiwara, Talia C Oughourlian, Nicholas S Cho, et al.
The Lancet. Oncology|November 8, 2015
Immunotherapy response assessment in neuro-oncology: a report of the RANO working groupHideho Okada, Michael Weller, Raymond Huang, et al.
NMR in Biomedicine|June 15, 2022
Amine-weighted chemical exchange saturation transfer magnetic resonance imaging in brain tumorsNicholas S Cho, Akifumi Hagiwara, Jingwen Yao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2010
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiformeAlbert Lai, Anh Tran, Phioanh L Nghiemphu, et al.
Neuroimage. Clinical|December 16, 2021
"Aerobic glycolytic imaging" of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imagingAkifumi Hagiwara, Jingwen Yao, Catalina Raymond, et al.
Frontiers in Oncology|April 4, 2022
Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable DiseaseJodi Goldman, Akifumi Hagiwara, Jingwen Yao, et al.
Neuro-Oncology|August 2, 2022
Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader studyPhilipp Vollmuth, Martha Foltyn, Raymond Y Huang, et al.
Neuro-Oncology|March 15, 2014
Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacyDavid E Piccioni, Julia Selfridge, Reema R Mody, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2017
Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II TrialsBenjamin M Ellingson, Elizabeth R Gerstner, Marion Smits, et al.
Pageof 13

Showing results (111-120 of 128) with videos related to

Sort By:
Pageof 13
Neuro-Oncology|October 15, 2014
Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD)Patrick Y Wen, Timothy F Cloughesy, Benjamin M Ellingson, et al.
Neuro-Oncology|December 5, 2021
Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitorsAkifumi Hagiwara, Talia C Oughourlian, Nicholas S Cho, et al.
The Lancet. Oncology|November 8, 2015
Immunotherapy response assessment in neuro-oncology: a report of the RANO working groupHideho Okada, Michael Weller, Raymond Huang, et al.
NMR in Biomedicine|June 15, 2022
Amine-weighted chemical exchange saturation transfer magnetic resonance imaging in brain tumorsNicholas S Cho, Akifumi Hagiwara, Jingwen Yao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2010
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiformeAlbert Lai, Anh Tran, Phioanh L Nghiemphu, et al.
Neuroimage. Clinical|December 16, 2021
"Aerobic glycolytic imaging" of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imagingAkifumi Hagiwara, Jingwen Yao, Catalina Raymond, et al.
Frontiers in Oncology|April 4, 2022
Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable DiseaseJodi Goldman, Akifumi Hagiwara, Jingwen Yao, et al.
Neuro-Oncology|August 2, 2022
Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader studyPhilipp Vollmuth, Martha Foltyn, Raymond Y Huang, et al.
Neuro-Oncology|March 15, 2014
Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacyDavid E Piccioni, Julia Selfridge, Reema R Mody, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2017
Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II TrialsBenjamin M Ellingson, Elizabeth R Gerstner, Marion Smits, et al.
Pageof 13